Indication
Complement Abnormality
3 clinical trials
3 products
Product
EculizumabClinical trial
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH StudyStatus: Terminated, Estimated PCD: 2021-12-07
Clinical trial
Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 GlomerulopathyStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AliskirenProduct
Enalapril